Background: Olanzapine, a thienobenzodiazepine, is one of the relatively new atypical antipsychotic drugs. The lowest threshold of effective olanzapine plasma levels in inpatient treatment is assumed to be 9 ng/ml [28]. Very little is known about the plasma concentration in patients at various oral doses of olanzapine or about the clinically relevant interactions with co-medications. Methods: In 71 schizophrenic patients (age 32.6 ± 12.1, range 18-63 years; 31 women, 40 men), plasma olanzapine levels were assessed in 377 tests by high-performance liquid chromatography (HPLC) with electrochemical detection. Fifty-six of these plasma levels were assessed while patients were receiving olanzapine as monotherapy; otherwise, the plasma levels were assessed with the patients receiving various co-medications. Results: The mean daily oral dose of olanzapine was 17.5 mg (SD = 7.0, range 5-40 mg), and the mean olanzapine plasma concentration was 54.2 ng/ml (SD 37.8 ng/ml, range 1.2-208 ng/ml). The plasma concentration of olanzapine increased linearly with the daily oral dose (r = 0.64, p < 0.001). A multiple variance analysis considering age and sex as covariables showed a significant difference in the dose-corrected plasma levels of olanzapine among 40 smokers and 31 non-smokers; age and sex did not affect the dose-corrected plasma levels. However, women received a significantly lower daily dose of olanzapine under routine clinical study conditions. No differences could be detected among the dose-corrected plasma concentration of those patients who were taken off olanzapine because they did not respond (n = 14) or because of side effects (n = 5) and those who were discharged while still on olanzapine. Under the co-medication with fluvoxamine, significantly higher dose-corrected olanzapine plasma concentrations were found than with olanzapine monotherapy, whereas significantly lower dose-corrected olanzapine plasma concentrations were detected under lithium and trimipramine co-medication. Under co-medication with amitriptyline, benperidol, carbamazepine, flupentixol, and lorazepam, the dose-corrected olanzapine plasma concentrations were no different than the plasma levels under olanzapine monotherapy. Conclusions: The relevance of therapeutic drug monitoring is emphasized with respect to the data presented and to the literature. Future studies should examine, in particular, the effects of a wider range of co-medications in a larger patient sample.
References
-
1
Aravagiri M, Ames D, Wirshing W C, Marder S R.
Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.
Ther Drug Monit.
1997;
19
307-313
-
2
Baptista T, Kin N MKNY, Beaulieu S, de Baptista E A.
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Pharmacopsychiatry.
2002;
35
205-219
-
3
Beasley C M, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S.
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.
Psychopharmacology.
1996;
124
159-167
-
4
Beasley C M, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton M S, and The Olanazapine HGAD Study G roup.
Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial.
Neuropsychopharmacology.
1996;
14
112-123
-
5
Bergström R F, Callaghan J T, Cerimele B J.
Pharmacokinetics of olanzapine in elderly and young.
Pharm Res.
1995;
12
358 (suppl.)
-
6
Bever K A, Perry P J.
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
Am J Health-Syst Pharmacists.
1998;
55
1003-1016
-
7
Brown E S, Thomas N R, Carmody T, Mahadi S, Nejtek V A.
Atypical antipsychotics in bipolar and schizoaffective disorders.
Pharmacopsychiatry.
2001;
34
80-81
-
8
Bymaster F P, Calligaro D O, Falcone J F, Marsh R D, Moore N A, Tye N C, Seeman P, Wong D T.
Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Neuropsychopharmacology.
1996;
14
87-96
-
9
Callaghan J T, Cerimele B J, Kassahun K J, Nyhart E H, Hoyes-Beehler P J, Kondraske G V.
Olanzapine: interaction study with imipramine.
J Clin Pharmacol.
1997;
37
971-978
-
10
Callaghan J T, Bergstrom R F, Ptak L R, Beasley C M.
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Clin Pharmacokinet.
1999;
3
177-193
-
11
Casey D E.
Side effect profiles of new antipsychotic agents.
J Clin Psychiat.
1996;
57
40-52
-
12
Catlow J T, Barton R D, Clemens M, Gillespie T A, Goodwin M, Swanson S P.
Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection.
J Chromatogr B: Biomedical Applications.
1995;
668
85-90
-
13
Chiu J A, Franklin R B.
Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection.
J Pharmaceut Biomed Anal.
1996;
14
609-615
-
14
Chouinard G, Lefko-Singh K, Teboul E.
Metabolism of anxiolytics and hypnotics: benzodiazepins, buspirone, zoplicone, and zolpidem.
Cell Mol Neurobiol.
1999;
19
533-552
-
15
Daniel W, Netter K J.
Alteration of cytochrome P-450 by prolonged administration of imipramine and/or lithium to rats.
Naunyn Schmiedebergs Arch Pharmacol.
1990;
342
234-240
-
16
Ereshefsky L.
Pharmokinetics and drug interactions: update for new antipsychotics.
J Clin Psychiat.
1996;
57
12-25 (suppl. 11)
-
17
Fulton B, Goa K L.
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
Drugs.
1997;
53
281-298
-
18
Gaertner H J, Gaertner I, Lampe D.
Therapeutisches Drug-Monitoring von Clozapin und Olanzapin.
Psychopharmakotherapie.
1999;
6
105-109
-
19
Kassahun K, Mattiuz E, Nyhart J rE.
Disposition and biotransformation of the antipsychotic agent olanzapine in humans.
Drug Metab Dispos.
1997;
25
81-93
-
20
Kelly D L, Conley R R, Tamminga C A.
Differential olanzapine plasma concentrations by sex in a fixed-dose study.
Schizophren Res.
1999;
40
101-104
-
21
Licht R W, Olesen O V, Friies P, Laustsen T.
Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.
J Clin Psychopharmacol.
2000;
20
110-112
-
22
Lucas R A, Gilfillan D J, Bergstrom R F.
A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
Eur J Clin Pharmacol.
1998;
54
639-643
-
23
Mäenpää M D, Wrighton S, Bergstrom R, Cerimele B, Tatum D, Hatcher B, Callaghan J T.
Pharmacokinetic and pharmacodynamic interactions between fluvoxamine and olanzapine.
Clinical Pharmacol Ther.
1998;
61
225
-
24 Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Bremen; UNI-MED 1999
-
25
Nemeroff C B.
Dosing the antipsychotic medication olanzapine.
J Clin Psychiat Monograph.
1997;
15
24-26
-
26
Olesen O V, Linnet K.
Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
Ther Drug Monit.
1999;
21
87-90
-
27
Patel B R, Nyhart J rEH, Callaghan J T.
Combined population pharmacokinetic analysis of olanzapine in healthy volunteers.
Pharm Res.
1995;
12
360 (suppl.)
-
28
Perry P J, Sanger T, Beasley C.
Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.
J Clin Psychopharmacol.
1997;
17
472-477
-
29
Pollock B.
Gender differences in psychotropic drug metabolism.
Psychopharmacol Bull.
1997;
33
235-241
-
30
Ring B J, Binkley S N, Vandenbranden M, Wrighton S A.
In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
British J Clinical Pharmacol.
1996;
41
181-186
-
31
Ring B J, Catlow J, Lindsay T J, Gillespie T, Roskos L K, Cerimele B J, Swanson S P, Mitchell A, Wrighton H, Wrighton S A.
Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.
J Pharmacol Exp Ther.
1996;
276
658-666
-
32
Tohen M, Chengappa K NR, Suppes T, Zarate D, Calabrese J R, Bowden C L, Sachs G S, Kupfer D J, Baker R W, Risser R C, Keeten E L, Feldman P D, Tollefson G D, Breier A.
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Arch Gen Psychiat.
2002;
59
62-69
-
33
Tollefson G D, Beasley C M, Tran P V, Street J S, Krueger J A, Tamura R N, Graffeo K A, Thieme M E.
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Am J Psychiat.
1997;
154
457-465
-
34
Tollefson G D, Sanger T M, Lu Y, Thieme M E.
Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol.
Arch Gen Psychiat.
1998;
55
250-258
-
35
Tollefson G D, Sanger T M.
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Am J Psychiat.
1997;
154
466-474
-
36 Tran P, Beasley C, Street J. Olanzapine versus haloperidol: acute results of the multi-center international trial. 20th Congress of the International College of Neuropsychopharmacology (CINP). Melbourne, Australia; 1996
-
37
Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A.
Decrease of energy expenditure cause weight increase in olanzapine treatment - a case study.
Pharmacopsychiatry.
2002;
35
124-126
-
38
Weigmann H, Gerek S, Zeisig A, Müller M, Härtter S, Hiemke C.
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.
Ther Drug Monit.
2001;
23
410-413
-
39
Yoshioka H, Ida S, Yokota M, Nishimoto A, Shibata S, Sugawara A, Takiguchi Y.
Effects of lithium on the pharmacokinetics of valproate in rats.
J Pharm Pharmacol.
2000;
52
297-301
Dr. med. Dipl.-Psych. Niels Bergemann
Department of Psychiatry, University of Heidelberg
Voss-Str. 4
D-69118 Heidelberg
Germany
Telefon: +49(0)6221/56-5411, -4466
Fax: +49(0)6221/56-5477
eMail: niels_bergemann@med.uni-heidelberg.de
